An Fc silenced anti-oxMIF antibody, comprising a variant Fc region of a wild-type human IgG comprising SEQ ID NO:1 with one or more amino acid substitutions or glycosylation modifications, and the following variable domains: a light chain variable domain comprising SEQ ID NO:2 with 1, 2, 3, 4, or 5 amino acid substitutions selected from M30L, F49Y, A51G, P80S, W93F, or a light chain variable domain comprising SEQ ID NO:2 with 1, 2, 3, 4, or 5 amino acid substitutions selected from M30L, F49Y, A51G, P80S, W93F and with 1, 2, 3, 4, or 5 further amino acid substitutions, with the proviso that the - conserved tyrosine at position 36 is preserved, and a heavy chain variable domain comprising SEQ ID NO:3; or a heavy chain variable domain comprising SEQ ID NO:3 with 1 or 2 amino acid substitutions selected from L5Q and W97Y, or a heavy chain variable domain comprising SEQ ID NO:3 with 1 or 2 amino acid substitutions selected from L5Q and W97Y, and 1, 2, 3, 4 or 5 further amino acid substitutions; wherein amino acid positions are numbered according to Kabat, wherein the variant Fc region exhibits decreased FcγR binding compared to the wildtype IgG1 Fc region, wherein the one or more amino acid substitutions in the variant Fc region are at any one of positions E233, L234, L235, G236, G237, P238, D265, S267, H268, N297, S298, T299, E318, L328, P329, A330, P331 of SEQ ID NO:1, specifically the amino acid substitutions are at positions L234 and L235, according to EU numbering index, and/or wherein the Fc region is aglycosylated, and wherein said antibody has reduced aggregation potential and reduced hydrophobicity compared to an antibody comprising SEQ ID NO:2 and SEQ ID NO:3 lacking the amino acid substitutions. a light chain variable domain comprising SEQ ID NO:2 with 1, 2, 3, 4, or 5 amino acid substitutions selected from M30L, F49Y, A51G, P80S, W93F, or a light chain variable domain comprising SEQ ID NO:2 with 1, 2, 3, 4, or 5 amino acid substitutions selected from M30L, F49Y, A51G, P80S, W93F and with 1, 2, 3, 4, or 5 further amino acid substitutions, with the proviso that the - conserved tyrosine at position 36 is preserved, and - conserved tyrosine at position 36 is preserved, a heavy chain variable domain comprising SEQ ID NO:3; or a heavy chain variable domain comprising SEQ ID NO:3 with 1 or 2 amino acid substitutions selected from L5Q and W97Y, or a heavy chain variable domain comprising SEQ ID NO:3 with 1 or 2 amino acid substitutions selected from L5Q and W97Y, and 1, 2, 3, 4 or 5 further amino acid substitutions; wherein amino acid positions are numbered according to Kabat, wherein the variant Fc region exhibits decreased FcγR binding compared to the wildtype IgG1 Fc region, wherein the one or more amino acid substitutions in the variant Fc region are at any one of positions E233, L234, L235, G236, G237, P238, D265, S267, H268, N297, S298, T299, E318, L328, P329, A330, P331 of SEQ ID NO:1, specifically the amino acid substitutions are at positions L234 and L235, according to EU numbering index, and/or wherein the Fc region is aglycosylated, and wherein said antibody has reduced aggregation potential and reduced hydrophobicity compared to an antibody comprising SEQ ID NO:2 and SEQ ID NO:3 lacking the amino acid substitutions.